Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation

Clinical Genetics

Volumn 85, Issue 1, 2014, Pages 21-30

  Metcalfe, K A ^a,b   Kim Sing, C ^c   Ghadirian, P ^d   Sun, P ^a   Narod, S A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

BRCA1 mutation; BRCA2 mutation; Cancer risk; Health care provider recommendations

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; OVARIECTOMY; OVARY CANCER; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION;

BRCA1 MUTATION; BRCA2 MUTATION; CANCER RISK; HEALTH CARE PROVIDER RECOMMENDATIONS;

ADULT; AGE FACTORS; AGE OF ONSET; BREAST NEOPLASMS; CANADA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HEALTH PERSONNEL; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MALE; MASTECTOMY; MIDDLE AGED; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS; OVARIECTOMY; PRACTICE GUIDELINES AS TOPIC; PREMEDICATION; QUESTIONNAIRES; TAMOXIFEN;

EID: 84890156706     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12233     Document Type: Article

References (19)

1. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003: 72: 1117-1130.
2. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian, National Comprehensive Cancer Network, Version 2, 2013.
3. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004: 22: 1055-1062.
4. Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005: 23: 7491-7496.
5. Kotsopoulos J, Lubinski J, Lynch HT et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012: 21: 1089-1096.
6. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006: 296: 185-192.
7. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002: 346: 1616-1622.
8. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001: 286: 2251-2256.
9. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004: 22: 2328-2335.
10. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008: 122: 2017-2022.
11. Metcalfe K, Ghadirian P, Rosen B et al. Variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers across Canada. Open Med 2007: 1: E92-E98.
12. Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Tamoxifen as chemoprevention in BRCA1/2 carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003: 21: 4322-4328.
13. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009: 101: 80-87.
14. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002: 346: 1609-1615.
15. Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE. Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008: 26: 5789-5796.
16. Houn F, Helzlsouer KJ, Friedman NB, Stefanek ME. The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health 1995: 85: 801-805.
17. Dhar SU, Cooper HP, Wang T et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 2011: 129: 221-227.
18. Julian-Reynier C, Eisinger F, Moatti JP, Sobol H. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 2000: 8: 204-208.
19. Bouchard L, Blancquaert I, Eisinger F et al. Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med 2004: 58: 1085-1096.